The National Reference Laboratory (NRL) participated as an Exhibitor at the 5th Neurology Congress, held from 21 to 23 February. As part of our commitment to advancing neurological diagnostics, NRL showcased its latest innovations in the early detection of Alzheimer’s disease and related neurodegenerative disorders.
This included advanced, non-invasive biomarker testing designed to support accurate diagnosis, disease monitoring, and improved clinical decision-making.
Through engagement with neurologists, clinicians, and healthcare partners, NRL reinforced its role in strengthening precision-led neurological care and promoting evidence-based approaches to cognitive health across the region.
